GlassScriptPhysician profile
Byron S Ladd
NPI 1619086634
$7,336.33
in general payments reported to CMS, 2019-2025
17 companies · $2,468 in 2025
The $2,468 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $73.22 · 2021: $875 · 2022: $679 · 2023: $1,782 · 2024: $841 · 2025: $2,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,591 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,591.30 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $2,757.80 | 2019-2025 | Foresee Home |
| Ocular Therapeutix, INC. | $1,552.12 | 2023-2025 | Dextenza |
| Genentech USA, INC. | $558.44 | 2019-2025 | Vabysmo |
| Alimera Sciences, INC. | $475.68 | 2022-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $452.64 | 2020-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $304.73 | 2024-2025 | Izervay |
| Alcon Vision LLC | $226.07 | 2021-2025 | Centurion, Clareon, Lensx |
| Genentech, INC. | $210.38 | 2023 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $192.60 | 2019-2021 | |
| Allergan, INC. | $166.41 | 2021 | |
| Harrow Eye, LLC | $129.15 | 2024-2025 | Iheezo, Triesence |
| Coherus Oncology, INC. | $128.55 | 2022-2023 | |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Abbvie INC. | $48.43 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $22.55 | 2023 | Syfovre |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $22.22 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byron Ladd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.